FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR Coronavirus reports – Part 8: “Going into hospital during this time... December 18, 2020 Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... March 16, 2023 Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... March 31, 2022 Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors November 15, 2019 Load more HOT NEWS 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... Liquid Biopsies on the Horizon for Children with Solid Cancers Pursuing precision medicine in a flagship lung cancer trial
